Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price target on the stock. CMPX has been the topic of several other reports. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” […]
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price target on the stock. CMPX has been the topic of several other reports. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” […]
